These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 22234149)

  • 1. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
    Johansen OE; Neubacher D; von Eynatten M; Patel S; Woerle HJ
    Cardiovasc Diabetol; 2012 Jan; 11():3. PubMed ID: 22234149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
    Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
    Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
    Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
    JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N; Rosenstock J; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Espeland MA; Bluhmki E; Mattheus M; Ryckaert B; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin. Avoid gliptins!
    Prescrire Int; 2013 Feb; 22(135):36-7. PubMed ID: 23444496
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
    Schernthaner G; Barnett AH; Patel S; Hehnke U; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1078-86. PubMed ID: 24865132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR; Swallow R; Dugi KA; Woerle HJ
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
    McInnes G; Evans M; Del Prato S; Stumvoll M; Schweizer A; Lukashevich V; Shao Q; Kothny W
    Diabetes Obes Metab; 2015 Nov; 17(11):1085-92. PubMed ID: 26250051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S; Patel S; Crowe S; von Eynatten M
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
    Cobble ME; Frederich R
    Cardiovasc Diabetol; 2012 Jan; 11():6. PubMed ID: 22248301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.